Hepta, founded by former Grail veterans, published proof‑of‑concept data showing cell‑free DNA (cfDNA) methylation signatures reflect liver tissue biology, including fibrosis and pathway activity. The company assembled a multiomic liver atlas with single‑cell and bulk data and matched plasma cfDNA methylation to tissue signatures, supporting noninvasive detection and staging of metabolic dysfunction‑associated steatohepatitis (MASH). Hepta positioned the findings as validation for methylation‑based liquid biopsy diagnostics in chronic liver disease and a potential route to clinical assays that stratify patients by disease biology rather than only by protein biomarkers.